Item 8.01. Other Events.
OnDecember 30, 2022 ,BeiGene, Ltd. ("BeiGene") announced that theCenter for Drug Evaluation of theChina National Medical Products Administration has accepted a supplemental biologics license application for tislelizumab in patients with first-line unresectable or metastatic hepatocellular carcinoma. The full text of this press release is filed as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.
Item 9.01. Financial Statements and Exhibits.
(d) Exhibits. Exhibit No. 99.1 Press release titled "BeiGene Announces Acceptance of 12th Regulatory Submission inChina for PD-1 Inhibitor
Tislelizumab" issued by
onDecember 30, 2022 104 The cover page from this Current Report on Form
8-K, formatted in Inline XBRL
--------------------------------------------------------------------------------
© Edgar Online, source